Korsana Biosciences, Inc. (KRSA) Income Statement
KRSA 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsKRSA revenue and net income
Where KRSA's revenue goes
2025Each bar shows an amount and its share of revenue. KRSA kept −170.1% of revenue as net income.
KRSA profit margins
KRSA growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +3.7% | +91.1% | −2.0% | — |
| Gross profit | +3.7% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
KRSA quarterly EPS vs estimates
Korsana Biosciences beat the analyst EPS estimate in 1 of the last 1 quarters. Next report: November 11, 2026 (estimate $-0.78).
KRSA income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.1M | $2.0M | $0 | $297,000 | $3.3M | $2.3M | $4.5M | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $1.3M | $5.6M | $0 | $56.4M | $95.1M | $1.5M | $1.7M | $2.2M |
| Gross profit | $2.1M | $2.0M | −$1.3M | −$5.3M | $3.3M | −$54.1M | −$90.6M | −$1.5M | −$1.7M | −$2.2M |
| Research & development | $959,000 | $286,000 | $1.5M | $6.0M | $37.6M | $56.4M | $95.1M | $87.7M | $78.8M | $50.9M |
| Sales, general & admin | $6.1M | $5.3M | $8.3M | $12.9M | $20.6M | $28.8M | $34.4M | $27.5M | $15.1M | — |
| Total operating expenses | $7.0M | $5.6M | $11.6M | $13.3M | $58.5M | $27.1M | $34.4M | $115.3M | $93.9M | $61.4M |
| Operating income | −$5.0M | −$3.6M | −$13.0M | −$18.5M | −$55.2M | −$81.3M | −$125.0M | −$115.3M | −$93.9M | −$63.6M |
| Interest income | $1.6M | $21,000 | — | — | — | — | — | — | — | — |
| Interest expense | — | — | — | — | $16,000 | — | — | — | — | — |
| Income before taxes | −$3.5M | −$3.1M | −$12.6M | −$18.2M | −$51.6M | −$77.8M | −$123.0M | −$115.3M | −$93.9M | −$63.6M |
| Net income | −$3.5M | −$3.1M | −$5.3M | −$44.1M | −$51.6M | −$77.8M | −$123.0M | −$115.3M | −$93.9M | −$63.6M |
| EBITDA | −$3.5M | −$3.1M | −$9.6M | −$18.2M | −$53.8M | −$80.6M | −$122.3M | −$113.7M | −$92.2M | −$61.4M |
| EPS (diluted) | −$6.96 | −$8.56 | −$18.24 | −$141.97 | −$189.75 | −$361.87 | −$627.40 | −$590.13 | −$479.93 | — |
| Gross margin | 100.0% | 100.0% | — | −1,778.5% | 100.0% | −2,357.1% | −2,010.9% | — | — | — |
| Operating margin | −239.8% | −181.4% | — | −6,242.4% | −1,662.5% | −3,539.4% | −2,774.3% | — | — | — |
| Net margin | −170.1% | −152.8% | — | −14,841.1% | −1,555.6% | −3,388.6% | −2,729.3% | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $1.0M | $875,000 | $93,000 | $81,000 | $1.8M | $194,000 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $730,000 | $0 | $0 | $0 | $0 | $0 | $0 | $105,000 | $44,000 | — | $580,000 |
| Gross profit | — | −$730,000 | $1.0M | $875,000 | $93,000 | $81,000 | $1.8M | $194,000 | −$105,000 | −$44,000 | — | −$580,000 |
| Research & development | — | $730,000 | $519,000 | $348,000 | $56,000 | $36,000 | $56,000 | $81,000 | $105,000 | $44,000 | $24,000 | $580,000 |
| Sales, general & admin | $1.8M | $2.5M | $1.3M | $1.5M | $1.7M | $1.5M | $1.2M | $1.2M | $1.3M | $1.6M | $1.8M | $2.1M |
| Total operating expenses | $1.8M | $2.5M | $1.9M | $1.9M | $1.8M | $1.5M | $1.3M | $1.3M | $1.3M | $1.6M | $1.8M | $5.4M |
| Operating income | −$1.8M | −$3.2M | −$838,000 | −$1.0M | −$1.7M | −$1.5M | $502,000 | −$1.1M | −$1.4M | −$1.6M | −$1.8M | −$6.0M |
| Income before taxes | −$1.8M | −$3.2M | −$799,000 | −$976,000 | −$324,000 | −$1.4M | $530,000 | −$723,000 | −$1.3M | −$1.5M | −$1.7M | −$5.9M |
| Net income | −$1.8M | −$3.2M | −$799,000 | −$976,000 | −$324,000 | −$1.4M | $530,000 | −$723,000 | −$1.3M | −$1.5M | −$1.7M | $7.6M |
| EBITDA | −$1.8M | −$3.2M | −$799,000 | −$976,000 | −$324,000 | −$1.4M | $530,000 | −$723,000 | −$1.3M | −$1.5M | −$1.7M | −$2.7M |
| EPS (diluted) | −$2.89 | −$5.29 | −$0.19 | −$2.12 | −$0.74 | −$3.91 | $1.46 | −$2.00 | −$3.69 | −$4.33 | −$4.79 | $21.75 |
| Gross margin | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — | — |
| Operating margin | — | — | −81.8% | −115.0% | −1,797.8% | −1,798.8% | 27.8% | −581.4% | — | — | — | — |
| Net margin | — | — | −78.0% | −111.5% | −348.4% | −1,764.2% | 29.3% | −372.7% | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in KRSA's financial statements (latest annual report filed December 31, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
KRSA financial results
In fiscal year 2025 (ended December 31, 2025), Korsana Biosciences reported revenue of $2.1 million, up 3.7% from the year before. It had a net loss of $3.5 million, a net profit margin of −170.1%. Diluted earnings per share came to −$6.96. Over five years revenue grew at an average rate of −2.0% a year.
See the KRSA stock overview for the latest quote and news, or the KRSA chart for price history and technical indicators.
KRSA income statement FAQ
What is Korsana Biosciences's annual revenue?
Korsana Biosciences reported total revenue of $2.1 million for fiscal year 2025, which ended on December 31, 2025. That was up 3.7% from $2.0 million the previous year.
Is Korsana Biosciences profitable?
No. Korsana Biosciences reported a net loss of $3.5 million in fiscal 2025, a net profit margin of −170.1%; its operating margin was −239.8%.
What is Korsana Biosciences's gross margin?
Korsana Biosciences's gross margin was 100.0% in fiscal 2025: for every $100 of revenue, Korsana Biosciences kept $100 after the direct cost of its products and services.
How much does Korsana Biosciences spend on research and development?
Korsana Biosciences spent $1.0 million on research and development in fiscal 2025, 46.2% of revenue.
How fast is Korsana Biosciences growing?
Revenue grew −2.0% a year on average over the last five fiscal years, from $2.3 million to $2.1 million.
What are Korsana Biosciences's earnings per share?
Korsana Biosciences earned $-6.96 per diluted share in fiscal 2025, compared with $-8.56 a year earlier.
When will Korsana Biosciences report its next earnings?
Korsana Biosciences is expected to report results for the quarter ending September 30, 2026 on November 11, 2026.
When does Korsana Biosciences's fiscal year end?
Korsana Biosciences's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on December 31, 2025.